SELLAS Life Sciences Group, Inc. (SLS) is a late-stage clinical biopharmaceutical company specialized in the development of novel cancer immunotherapies for a broad range of cancer indications. The company, incorporated in 2012 and headquartered in New York City, is listed on the NASDAQ under the ticker symbol "SLS".
SELLAS’ mission is to develop innovative treatments for cancer patients worldwide, with a focus on advancing immunotherapeutics and providing new therapeutic options for patients whose cancers are not responsive to current standard oncology treatments. The company uses a precision medicine approach to develop its products, identifying the unique genetic or protein changes in a patient’s cancer and designing therapies to specifically target these changes.
Their lead product candidate is galinpepimut-S (GPS), an immunotherapeutic agent that is in various stages of development for multiple types of cancer, including acute myeloid leukemia (AML), multiple myeloma (MM), and ovarian cancer. The therapy has obtained fast track and orphan drug designations from the FDA for these indications.
SELLAS also develops nelipepimut-S (NPS), an investigational immunotherapy that targets the HER2/neu protein. NPS is being developed for the treatment of patients with breast cancer that express the HER2/neu protein.
The development of these innovative cancer treatments speaks to the company's commitment to scientific and clinical excellence. Although the company is still in the clinical phase, these advancements in the pipeline demonstrate a promising trajectory.
The Company's management and board have noteworthy tenures within the pharmaceutical industry, bringing valuable experience and knowledge, making SELLAS Life Sciences Group well positioned to bring these new cancer treatments to market.
The company's strategy includes partnerships with well-established pharmaceutical companies to ensure they have the resources necessary to complete the expensive clinical phase. Over the years, SELLAS has established itself within the oncology space through peer-reviewed publications and presentations at top oncology conferences.
SELLAS Life Sciences Group, Inc. (SLS) adheres to stringent ethical, scientific, and clinical standards in their research and development process. They are driven by a commitment to innovation and the ambition to improve the lives of patients who are battling cancer. The company's work in advancing cancer research and drug development represents its pledge to make a significant difference in the field of oncology.